Aktienanalyse zu Organogenesis Holdings Inc (ORGO)ORGOOrganogenesis Holdings Inc

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Organogenesis Holdings Inc is not a good buy right now due to significant financial challenges and a declining stock price. The current price is $1.74, which is down 62.46% year-to-date, and the company has reported a net loss of $99,339,000 in Q2 2026. Additionally, the RSI is at 37.88, indicating that the stock is oversold, but this does not guarantee a price rebound. The main risk is the company's declining revenue and profitability, with a projected revenue decline of 45% to 52% for 2026.